Further in vivo data showed PSMA-TTC was associated with delayed tumor growth/tumor regression in PSMA-positive patient- and cell line-derived xenograft models mimicking different prostate cancer stages, including models resistant to standard-of-care anti-androgens (including enzalutamide) (61). This evidence concerns the gene FOLH1 and neoplasm.